Asthma & Allergies
» Changing Landscape of Treatment Options for ALL with CD19, CD22 Monoclonal Antibodies and AML with IDH1/2, FLT3, CD33 and Hedgehog Pathway Targeted Agents
Changing Landscape of Treatment Options for ALL with CD19, CD22 Monoclonal Antibodies and AML with IDH1/2, FLT3, CD33 and Hedgehog Pathway Targeted Agents
September 17, 2019
Strategy to Overcome Rituximab Resistance in Patients with Indolent Lymphoma
Is Prescribing Bed Rest Unethical?
Post a comment to this article
(will not be displayed)
Report Abusive Comment
Thank you for helping us to improve our forums. Is this comment offensive? Please tell us why.